LifeTech Scientific Corporation (Stock Code: 1302.HK) is the leading supplier of minimally invasive interventional medical devices to treat cardiovascular diseases. The company specializes in R&D, manufacture and sales, and its high-quality, innovative, proprietary products are extensively marketed in more than 100 countries by over 300 distributors. At present, the company is the world second largest supplier (and the largest among BRIC countries) of occluders to treat congenital heart diseases and the second largest supplier of aortic repair device in Asia Pacific.
Lifetech Scientific (Shenzhen) Co., Ltd., the subsidiary of Lifetech, was established in 1999, and other subsidiaries and sales offices were subsequently setup in Hong Kong, India, Netherland, France, Russia, America, Greece, Beijing, Shanghai, Guangzhou and etc. In November 2011, the company was successfully listed on the Hong Kong Stock Exchange with the market cap nearly 10 billion HKD.
As a result of its pursuit for quality and innovation, the quality system of LifeTech Scientific Corporation was accredited by the DEKRA in EU (ISO13485：2003), and passed inspection of Good Manufacturing Practice for Chinese Medical Devices. The company was rated as a National High-Tech Enterprise in 2008, and has obtained scientific research qualifications such as National Post-Doctoral Research Center, National and Local Joint Engineering Laboratory, etc. The company has also undertaken more than 50 government research projects, including the National Key Technology Research and Development Program of China under the “Tenth Five-Year Plan, the National Basic Research Program (973 Program) and the National High Technology Research and Development Program of China (863 Program). At the end of 2017, 6 products of the company have been approved as innovative medical devices by China Food and Drug Administration (CFDA).
Going forward, LifeTech Scientific Corporation is committed to enriching its product portfolio, improving product quality and enhancing medical services, to provide safe and innovative medical devices for doctors and patients globally and consistently contribute to the development of the industry.
To become a global leader in providing innovative medical devices for the treatment of cardiovascular diseases.
To provide doctors and patients around the world with safe and innovative cardiovascular medical devices.
Vision
Through our advanced technology and innovative spirit, we aim to become the worldwide leader in minimally invasive medical devices for cardiovascular diseases and disorders.
Innovation
Our innovation is inspired by our users: doctors. Because of this we are seen as the preferred partner in developing and providing life-saving medical technology.
Passion
Our passion is to strive for perfection and serve our customers and patient’s needs through our Lifetech brand products and services. Our product quality, sales, marketing and distribution expertise, combined with our government partnerships has enabled us to win our customer’s support as the leading provider of medical devices.
Teamwork
We believe that together we can achieve anything. Therefore our company is built around teamwork, collaboration and communication. We recognize every employee as a vital member to our team and strive to build a synergistic culture to achieve the impossible.
Executive Directors、Chairman and CEO
Executive Directors、Vice Prerident and CFO
Non-executive Directors
Independent non-executive Directors
Independent non-executive Directors
Independent non-executive Directors
The FIM for the IBS™ sirolimus-eluting iron absorbable coronary stent system was approved
Strategic cooperation with All Bridge Group
The [YY/T 1553-2017 industrial standard for Cardiovascular implants and Cardiac occluders] developed predominantly by LifeTech was approved by CFDA and brought into practice
Iliac Bifurcation Stent Graft System- The 6th product entered CFDA Green Channel
LAmbre™ LAAO & HeartTone™ pacemark was approved by CFDA
LAmbre™ LAAO was approved by CE
Pacemaker production line was established
Pacemaker workshop was established in Shenzhen
The advanced animal laboratory was established in Shenzhen
Constituent stock of Hang Seng index
Second prize of National Technological Invention Award
LAmbre™ and IBS™ entered CFDA green channel
CeraFle™ became the first Chinese brand entered the mainstream western market
National and local joint engineering laboratory of Interventional Medical Biotechnology
Strategic cooperation with Medtronic
Listed on the Hong Kong Stock Exchange(stock code:1302.HK)
Approved postdoctoral research stations
SeQur™ Snare -First product received FDA clearance
Cer™ ASD/VSD/PDA Occluders- First product series obtained CE mark approval
Certified as National high-tech enterprise
Invested by US.VC fund
Certified as Shenzhen high-tech enterprise
HeartR™ PDA Occluder –First product was approved by CFDA
Lifetech Scientific （Shenzhen）Co.Ltd., establishment
We have established a well-developed sales, marketing and distribution network. We have over 180 distributors worldwide; including more than 30 distributors covering Europe, North America, South America, Asia and Africa.
We primarily focus on fast growing, emerging and/or underserved markets and will continue to move into more mature markets proactively in the future.
Over 50overseas distributors
Over 130domestic distributors
We have a professional marketing team to work on internal sales training and dealer management, formulating the best industry standards, assessing market opportunity, and maintaining client relations and direct interaction with physicians and hospitals.
Our brand value is built on the basis of professional education, evidence-based medicine and knowledge sharing. Therefore, we created LKEP program (Lifetech Knowledge Exchange Program) in 2011. This platform is created to facilitate the knowledge exchange between physicians from different regions. So far, we have set up a great number of exchange centres; Experts from Europe, Latin American and Asia have participated in LKEP program and have done cases to share their techniques, experiences and feedbacks.
We are devoted to promote our product through professional training and patient education. We have set up international training centers for interventional therapy of congenital heart disease in Brazil, Italy, India, Greece, as well as Beijing, Shanghai, Guangzhou, Harbin, Tianjin, and Guangxi.
Quality Policy
We are committed to providing doctors and patients around the world with safe and innovative medical devices for the treatment of cardiovascular diseases.
We pledge that we will meet all regulatory requirements and maintain an effective quality management system.
The manufacturing process system adheres to the quality awareness with high standard and principles that strictly abide by and effectively implement it. Lifetech has employees with high quality and strict requirement from the general workers, technical personnel to management team.
All staff understand that Lifetech focuses on the implemental medical devices with high glory and adventures, and that to assure the quality is essential to the company’s reputation and patients’health. The sustained QCC and “Golden Idea” cultivate every employee’s awareness of the quality improvement involved by every one and costs controlling.
The gradually improved training mechanism crossing different products and with multi-skills and storing managing echelon staff are the strong strength and insurance for sustainable development.
The perfect process and systemized management mode, advanced equipment and flexible and fast and production are the strong cornerstone to satisfying the costumers’ individual needs.